Hedgehog signaling activation in human cancer and its clinical implications (Record no. 105993)

000 -LEADER
fixed length control field 03797nam a22004455i 4500
001 - CONTROL NUMBER
control field 978-1-4419-8435-7
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220083728.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 110429s2011 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781441984357
-- 978-1-4419-8435-7
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-4419-8435-7
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Xie, Jingwu.
Relator term editor.
245 10 - TITLE STATEMENT
Title Hedgehog signaling activation in human cancer and its clinical implications
Medium [electronic resource] /
Statement of responsibility, etc edited by Jingwu Xie.
250 ## - EDITION STATEMENT
Edition statement 1.
264 #1 -
-- New York, NY :
-- Springer New York,
-- 2011.
300 ## - PHYSICAL DESCRIPTION
Extent IX, 217 p.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Overview of hedgehog signaling pathway -- Regulation of Hh morphogene gradient -- Smoothened Signaling through a G-protein Effector Network.-  Kinases and phosphatases in hedgehog signaling -- Signaling Cross-talk of Oncogenic KRAS and Hedgehog Pathways in Pancreatic Cancer.- Crosstalks between PKC and hedgehog signaling.- Activation of Hh signaling in human cancer.-  Hedgehog signaling in pediatric brain tumors -- Hedgehog Signaling in Mammary Gland Development and Breast Cancer -- Hedgehog signaling and cancer therapeutic resistance.- Small-molecule Inhibitors of the Hedgehog Pathway.- Cyclopamine and its derivatives for cancer therapeutics.-.
520 ## - SUMMARY, ETC.
Summary, etc Despite significant progress in our understanding of cancer biology, cancer continues to be the second cause of human mortality. The remarkable responses of cancer patients to inhibitors to the hedgehog signaling pathway implies a promising novel approach to treat cancer. As a result, understanding the role of hedgehog signaling in cancer is critically important for novel cancer therapeutics. The hedgehog pathway, initially discovered by two Nobel laureates Drs. E. Wieschaus and C. Nusslein-Volhard in Drosophila, is a major pathway regulating cell differentiation, tissue polarity, stem cell maintenance and cell proliferation. It is known by now that activation of this pathway occurs in a variety of human cancer, including basal cell carcinomas (BCCs), medulloblastomas, leukemia, gastrointestinal, lung, ovarian, breast and prostate cancers. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. To provide the most up-to-date information on recent development in this exciting research area, we have invited experts in hedgehog signaling field to summarize major advances made in the last few years on hedgehog signaling mechanisms, activation of the pathway in various human cancer types, potential antagonists for hedgehog signaling inhibition and their clinical implications for human cancer treatment. Authors of the book have also highlighted current challenges in our efforts to translate the basic biology into clinic. This book provides insightful views suitable for graduate students, medical students, undergraduate students, basic and clinical scientists, cancer patients as well as the general public.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Toxicology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer Research.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmacology/Toxicology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781441984340
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4419-8435-7
912 ## -
-- ZDB-2-SBL

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue